GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE
Clinical trials for GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE explained in plain language.
Never miss a new study
Get alerted when new GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE trials appear
Sign up with your email to follow new studies for GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for brain cancer? experimental drug LMP744 targets recurrent glioblastoma
Disease control Not yet recruitingThis early-stage trial tests a new drug called LMP744 in 40 adults whose glioblastoma (a type of brain cancer) has come back after standard treatment. The drug is given through a vein for 5 days each month for up to a year. The goal is to see if it can shrink tumors or delay canc…
Matched conditions: GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) • Aim: Disease control
Last updated May 11, 2026 20:49 UTC
-
New brain injection shows promise for tough glioblastoma
Disease control Not yet recruitingThis study tests a new treatment called MT027 for people with a severe brain cancer (glioblastoma) that has come back. The treatment is given as an injection into the fluid around the brain. The goal is to see if it is safe and can help people live longer. About 40 adults aged 18…
Matched conditions: GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE
Phase: PHASE2 • Sponsor: T-MAXIMUM Pharmaceutical Inc • Aim: Disease control
Last updated May 06, 2026 16:03 UTC